Skip to main content

Anti-ganglioside antibodies and clinical outcome of patients with Guillain–Barré Syndrome in northeast Brazil

Buy Article:

$51.00 plus tax (Refund Policy)


Dourado ME, Duarte RC, Ferreira LC, Queiroz JW, Illa I, Perez-Perez G, Guerrant RL, Jerônimo SMB. Anti-ganglioside antibodies and clinical outcome of patients with Guillain–Barré Syndrome in northeast Brazil.

Acta Neurol Scand 2003: 108: 102–108. © Blackwell Munksgaard 2003. Objectives –

The goal of this study was to investigate the frequency of GM1 antibodies and to assess whether exposure to Campylobacter jejuni was associated with a distinct clinical variant of Guillain–Barré Syndrome (GBS) or disease outcome in Rio Grande do Norte, Brazil. Material and methods –

Forty-one patients with a presumed diagnosis of GBS were enrolled and prospectively studied between June 1994 and November 1999. Results –

Anti-GM1 was present in 51.2% (n = 21) of patients. The presence of anti-GM1 was significantly associated with acute axonal motor neuropathy when compared to acute inflammatory demyelinating polyneuropathy (P = 0.01). Patients with anti-GM1 antibodies presented distal muscle involvement and fewer sensory deficits. Age, time to nadir and ventilatory assistance were not associated with anti-GM1 antibodies. Eight out of 21 patients (32%) presented with anti-C. jejuni antibodies. Clinical features were similar for patients with GBS with positive and negative C. jejuni antibodies. Anti-GM1 antibodies were associated with C. jejuni infection (P = 0.0005). Presence of anti-GM1 and C. jejuni antibodies did not indicate a worse prognosis. Conclusion –

Patients with GBS and anti-GM1 antibodies had more distal muscle weakness, fewer sensory deficits, more axonal degeneration and C. jejuni infection, but these findings were not associated with a worse prognosis.

Keywords: Campylobacter jejuni; Guillain–Barré Syndrome; anti-ganglioside antibodies; gangliosides

Document Type: Research Article


Affiliations: 1: Departamento de Bioquímica, Centro de Biociências, 2: Department of Neurology, University of Barcelona, Barcelona, Spain; 3: Department of Medicine and Microbiology, New York University School of Medicine, New York, NY; 4: Department of Medicine, University of Virginia, Charlottesville, VA, USA

Publication date: August 1, 2003

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Partial Open Access Content
Partial Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more